Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
RKTO
vs
S&P 500
RKTO
S&P 500
Over the past 12 months, RKTO has underperformed S&P 500, delivering a return of -70% compared to S&P 500's +11% growth.
Stocks Performance
RKTO vs S&P 500
Performance Gap
RKTO vs S&P 500
Create a free account · No card needed
Performance By Year
RKTO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics is a clinical-stage biopharmaceutical company that develops drug candidates for diseases with limited treatment options, especially in areas like skin disorders, cancer, and inflammatory conditions. It does not sell a broad lineup of commercial medicines yet; instead, it works on turning its research programs into future therapies that can be tested in patients and, if successful, brought to market. Its main customers would eventually be patients, doctors, and healthcare systems, but today the company mostly deals with research partners, contract labs, regulators, and potential licensing partners. Hoth makes money, or aims to make money, through future product sales, licensing deals, and other partnerships if its drug candidates advance successfully. What makes Hoth different is that it is a small drug developer rather than a large pharmaceutical manufacturer. Its business depends on picking a few specific medical programs, funding their development, and finding a path to commercialization through its own efforts or through partners.
Create a free account · No card needed
